Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Childhood arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Childhood arthritis. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2007-000872-18 Sponsor Protocol Number: WA18221 Start Date*: 2008-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A 12-week randomized, double blind, placebo-controlled, parallel group, 2-arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthritis...
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) NO (Ongoing) CZ (Completed) ES (Completed) DK (Completed) NL (Completed) GR (Completed) SK (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000444-10 Sponsor Protocol Number: WA28029 Start Date*: 2012-11-09
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE IV STUDY TO EVALUATE DECREASED DOSE FREQUENCY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO EXPERIENCE LABORATORY ABNORMALITIES DURING TREATMENT WITH TOCILIZUMAB
    Medical condition: Systemic juvenile idiopathic arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) NO (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005479-82 Sponsor Protocol Number: CACZ885G2301 Start Date*: 2009-06-12
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio doble ciego, randomizado, controlado con placebo, con diseño de retirada en la prevención de brotes con canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica y manifes...
    Medical condition: Artritis idiopática juvenil sistémica y manifestaciones sistémicas activas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) NO (Ongoing) FR (Completed) HU (Completed) BE (Completed) DE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) AT (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004915-22 Sponsor Protocol Number: A3921145 Start Date*: 2012-08-03
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Trial now transitioned) DE (Completed) SK (Completed) IT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001438-46 Sponsor Protocol Number: A3921104 Start Date*: 2018-03-27
    Sponsor Name:Pfizer Inc.
    Full Title: EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004103-73 Sponsor Protocol Number: 0881A1-207 Start Date*: 2015-03-12
    Sponsor Name:Wyeth Kabushiki Kaisha (Wyeth K.K.)
    Full Title: A long-term, open-label study of TNR-001 in Japanese Juvenile Idiopathic Arthritis Subjects.
    Medical condition: Juvenile idiopathic arthritis (JIA)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001171-37 Sponsor Protocol Number: 20021626 Start Date*: 2012-03-07
    Sponsor Name:Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
    Full Title: A Phase IV Registry of Etanercept in Children With Juvenile Rheumatoid Arthritis
    Medical condition: Juvenile idiopathic arthritis (JIA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012520-84 Sponsor Protocol Number: 0881A1-3338 Start Date*: 2009-08-19
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate...
    Medical condition: Extended oligoarticular juvenile idiopathic arthritis (JIA) Enthesitis-related arthritis (ERA) Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003246 Arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) BE (Completed) CZ (Completed) FR (Completed) SI (Completed) ES (Completed) SE (Prematurely Ended) SK (Completed) LT (Completed) NL (Completed) LV (Completed) GR (Completed) DK (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000889-38 Sponsor Protocol Number: 2019/MyJIA Start Date*: 2020-09-16
    Sponsor Name:Oslo University Hospital
    Full Title: Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intra-articular glucocortico...
    Medical condition: Juvenile idiopathic arthritis is characterised by inflamed joints and is the most common chronic rheumatic disease in childhood and adolescence that potentially lead to disability due to joint dama...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001145-40 Sponsor Protocol Number: 20021618 Start Date*: 2012-03-07
    Sponsor Name:Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
    Full Title: Open-label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trials
    Medical condition: Rheumatoid arthritis (RA) in adults and juvenile idiopathic arthritis (JIA) for subjects who did not respond to conventional DMARDS
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003358-27 Sponsor Protocol Number: HUM06-037 Start Date*: 2008-05-02
    Sponsor Name:Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
    Full Title: Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab
    Medical condition: Juvenile ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    10 10002556 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002788-88 Sponsor Protocol Number: 20190529 Start Date*: 2021-01-11
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Yea...
    Medical condition: Juvenile psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004495-60 Sponsor Protocol Number: I4V-MC-JAHU Start Date*: 2019-09-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthrit...
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) DK (Prematurely Ended) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004668-71 Sponsor Protocol Number: 11/0499 Start Date*: 2014-09-25
    Sponsor Name:University College London
    Full Title: An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa
    Medical condition: Childhood systemic polyarteritis nodosa (PAN)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10036026 Polyarteritis nodosa of childhood LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) PT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000300-42 Sponsor Protocol Number: 03AR0298 Start Date*: 2013-01-18
    Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
    Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000119-10 Sponsor Protocol Number: I4V-MC-JAHW Start Date*: 2019-08-06
    Sponsor Name:Eli Lilly and Company
    Full Title: An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Ch...
    Medical condition: Juvenile Idiopathic Arthritis Associated Uveitis or Anterior Antinuclear Antibody-Positive Uveitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-002134-74 Sponsor Protocol Number: FLU-v004 Start Date*: 2016-07-27
    Sponsor Name:PepTcell Limited (trade name SEEK)
    Full Title: Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model
    Medical condition: Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005663-32 Sponsor Protocol Number: CAIN457A2310 Start Date*: 2015-08-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single blinded arm) after t...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Completed) DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 25 16:16:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA